Sensipar, Mimpara(cinacalcet)
Cinacalcet, Mimpara (cinacalcet) is a small molecule pharmaceutical. Cinacalcet was first approved as Sensipar on 2004-03-08. It is used to treat parathyroid neoplasms, primary hyperparathyroidism, and secondary hyperparathyroidism in the USA. It has been approved in Europe to treat hypercalcemia, hyperparathyroidism, parathyroid neoplasms, and secondary hyperparathyroidism. The pharmaceutical is active against extracellular calcium-sensing receptor. In addition, it is known to target metabotropic glutamate receptor 5.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Cinacalcet (discontinued: Cinacalcet, Sensipar)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cinacalcet | ANDA | 2025-12-12 |
| cinacalcet hydrochloride | ANDA | 2024-05-24 |
| sensipar | New Drug Application | 2025-12-07 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| parathyroid neoplasms | — | D010282 | — |
| secondary hyperparathyroidism | EFO_1001173 | D006962 | — |
| primary hyperparathyroidism | EFO_0008519 | D049950 | E21.0 |
Agency Specific
FDA
EMA
No data
HCPCS
Code | Description |
|---|---|
| J0604 | Cinacalcet, oral, 1 mg, (for esrd on dialysis) |
Clinical
Clinical Trials
86 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyperparathyroidism | D006961 | EFO_0008506 | E21.3 | 2 | 14 | 20 | 17 | 7 | 56 |
| Secondary hyperparathyroidism | D006962 | EFO_1001173 | — | 2 | 10 | 16 | 15 | 6 | 46 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 2 | 8 | 12 | 10 | 1 | 30 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | 5 | 11 | 7 | 1 | 24 |
| Chronic renal insufficiency | D051436 | — | N18 | 1 | 3 | 10 | 7 | 1 | 21 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | 6 | 5 | 4 | 1 | 16 |
| Primary hyperparathyroidism | D049950 | EFO_0008519 | E21.0 | — | 5 | 5 | 2 | 3 | 14 |
| Hypercalcemia | D006934 | HP_0003072 | E83.52 | 1 | 1 | 3 | 1 | — | 5 |
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | — | — | — | 2 | 1 | 3 |
| Parathyroid neoplasms | D010282 | — | — | — | — | 2 | 1 | — | 3 |
Show 9 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kidney transplantation | D016030 | — | — | — | — | 1 | — | 3 | 4 |
| Hypophosphatemia | D017674 | HP_0002148 | — | 1 | — | 1 | — | 1 | 3 |
| Parathyroid diseases | D010279 | — | E21.5 | — | — | 1 | — | — | 1 |
| Carcinoma | D002277 | — | C80.0 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic kidney disease-mineral and bone disorder | D012080 | EFO_1001152 | N25.0 | — | 2 | — | — | — | 2 |
| Prostatic neoplasms | D011471 | — | C61 | — | 1 | — | — | — | 1 |
| Recurrence | D012008 | — | — | — | 1 | — | — | — | 1 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | 1 | — | — | — | 1 |
| Inflammation | D007249 | MP_0001845 | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | 1 | 2 |
| Familial hypophosphatemic rickets | D053098 | — | — | 1 | — | — | — | 1 | 2 |
| Hypophosphatemic rickets | D063730 | — | E83.31 | 1 | — | — | — | 1 | 2 |
| Rickets | D012279 | EFO_0005583 | E55.0 | 1 | — | — | — | 1 | 2 |
| Osteomalacia | D010018 | EFO_1002027 | M83 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Calcium metabolism disorders | D002128 | EFO_0005769 | E83.5 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Cinacalcet |
| INN | cinacalcet |
| Description | Cinacalcet is a secondary amino compound that is (1R)-1-(naphthalen-1-yl)ethanamine in which one of the hydrogens attached to the nitrogen is substituted by a 3-[3-(trifluoromethyl)phenyl]propyl group. It has a role as a calcimimetic and a P450 inhibitor. It is a member of naphthalenes, a secondary amino compound and a member of (trifluoromethyl)benzenes. |
| Classification | Small molecule |
| Drug class | calcium-sensing receptor (CaSR) agonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12 |
Identifiers
| PDB | — |
| CAS-ID | 226256-56-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201284 |
| ChEBI ID | 48390 |
| PubChem CID | 156419 |
| DrugBank | DB01012 |
| UNII ID | UAZ6V7728S (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
GRM5
GRM5
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Cinacalcet
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,494 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
46,199 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use